Acolyte Biomedica, a UK based specialist in fighting the MRSA superbug, has been sold to US technology company 3M by its venture backers Angle, Porton Capital, Dstl/Ploughshare Innovations and Partnerships UK.
Acolyte Biomedica helps hospitals control high-risk infections through improved screening and targeted treatment of methicillin-resistant Staphylococcus aureus (MRSA), the well publicised bacteria that is resistant to certain antibiotics and occurs most frequently in hospital patients who have weakened immune systems.
The business is a UK joint venture company spun out of the Defence Science and Technology Laboratory (Dstl), the Ministry of Defence’s main centre of science. It has secured £3.7m in venture capital funding since its founding in 2000 with start-up financing from the Dstl and Angle. The company has exclusive rights to medical applications of a rapid bacterial testing method developed over 10 years within Dstl. Its products are based on technology used for detecting biological warfare, originally developed by Ministry of Defence.